Evidence map›Paper›PMID 33238202›Full record

ReviewCurrent opinion in immunology2020

Asthma-chronic obstructive pulmonary disease overlap syndrome.

Matthew F Mart, Ray Stokes Peebles

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Matthew F MartDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Ray Stokes PeeblesDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, United States; Tennessee Valley Healthcare System, United States Department of Veterans Affairs, Nashville, TN, USA. Electronic address: stokes.peebles@vumc.org.
Vanderbilt University Medical Center · USVA Tennessee Valley Healthcare System · US

Funding

Viral and Host Determinants of Infant and Childhood Allergy and AsthmaU19AI095227 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Tina V Hartert · 2011 to 2026
$34.9M
Clinical and Translational Training Program in Pulmonary MedicineT32HL087738 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Lorraine B Ware · 2007 to 2026
$7.0M
PGI2 augments Treg functionR01AI145265 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEBLES, RAY STOKES · 2019 to 2023
$2.7M
GLP-1R signaling in allergic inflammationR01AI124456 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI NISWENDER, KEVIN D, PEEBLES, RAY STOKES · 2017 to 2021
$2.2M
PGI2 regulation of TSLP-mediated allergic inflammation in the lungR01AI111820 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEBLES, RAY STOKES · 2014 to 2018
$2.0M
THE ROLE OF PROSTAGLANDIN D2 IN THE RESPIRATORY SYMPTOMS OF ASPIRIN EXACERBATED RESPIRATORY DISEASEK23AI118804 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CAHILL, KATHERINE N · 2015 to 2019
$951k
Host genetics of allergen-induced lung TSLP expression and ILC2 functionR21AI145397 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PEEBLES, RAY STOKES · 2019 to 2020
$468k
The role of cyclooxygenase in the adaptive immune response and toleranceI01BX000624 · VA · VETERANS HEALTH ADMINISTRATION · PI PEEBLES, RAY STOKES · 2009 to 2019
–
PGI2 regulation of CD4+ Th2 metabolism in allergic airway inflammationI01BX004299 · VA · VETERANS HEALTH ADMINISTRATION · PI PEEBLES, RAY STOKES · 2019 to 2025
–
BLRD VA I01 BX000624BLRD VA I01 BX004299NHLBI NIH HHS T32 HL087738NIAID NIH HHS K23 AI118804NIAID NIH HHS R01 AI111820NIAID NIH HHS R01 AI124456NIAID NIH HHS R01 AI145265NIAID NIH HHS R21 AI145397NIAID NIH HHS U19 AI095227
6 · The paper itself

Abstract

Overlap of asthma and chronic obstructive lung disease (ACO) in patients with obstructive lung disease is growing in recognition, though there is no consistent agreement on the diagnostic criteria for the disease process. Patients with ACO have distinct clinical characteristics and trajectories, which are representative of a heterogenous, multifactorial, and incompletely understood inflammatory pathophysiology. Current treatment strategies are focused on titration of inhaled therapies such as long-acting bronchodilators, with increasing interest in the use of targeted biologic therapies aimed at the underlying inflammatory mechanisms. Future directions for research will focus on elucidating the varied inflammatory signatures leading to ACO, the development of consistent diagnostic criteria and biomarkers of disease, and improving the clinical management with an eye toward targeted therapies.

Indexed as

AsthmaAsthma-Chronic Obstructive Pulmonary Disease Overlap SyndromeBiomarkersHumansBiomarkers

Identifiers

PMID33238202
PMCPMC7749033
OpenAlexW3107279930

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.